PRX-112
PB-112-02a
Phase 2 small_molecule completed
Quick answer
PRX-112 for Gaucher Disease is a Phase 2 program (small_molecule) at Protalix BioTherapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Gaucher Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed